Clearside Biomedical, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Alparetta Georgia (2011)

Organization Overview

First Clinical Trial
2013
NCT01789320
First Marketed Drug
2021
triamcinolone (kenalog)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

CLEARSIDE | Clearside Biomedical, Inc.

Active Ingredients

Marketed Drugs (1)

triamcinolone (kenalog) (2021)

Drugs in Phase 3 Trials (4)

aflibercept (zaltrap) (5 trials)

bevacizumab (avastin) (1 trial)

ranibizumab (lucentis) (1 trial)

triamcinolone (kenalog) (7 trials)

Drugs in Phase 2 Trials (1)

axitinib (inlyta) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Edema (Phase 3)

Macular Degeneration (Phase 2)

Macular Edema (Phase 3)

Panuveitis (Phase 3)

Pars Planitis (Phase 3)

Retinal Vein Occlusion (Phase 3)

Uveitis (Phase 3)

Uveitis, Anterior (Phase 3)

Uveitis, Intermediate (Phase 3)

Uveitis, Posterior (Phase 3)

Wet Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 5